Opinion|Videos|February 4, 2025
Strategic Use of Bispecific Antibodies in R/R MM
Panelists discuss at what line of therapy bispecific antibodies are considered in treatment decision-making, whether they are used earlier or later in the sequence, and the factors influencing that choice, including weighing bispecifics against other options like chimeric antigen receptor (chimeric antigen receptor) T or standard therapies. They also address the clinical and molecular factors that guide the selection between B-cell maturation antigen (BCMA)– and GPRC5D-targeting bispecifics and comment on the study exploring talquetamab as a bridging strategy before BCMA CAR T therapy, highlighting the potential impact of bispecifics in this treatment paradigm.
Advertisement
Video content above is prompted by the following:
- At what line of therapy do you consider bispecific antibodies in your treatment decision-making? Are you using them earlier or later in the treatment sequence, and what factors influence that decision?
- How do you weigh bispecific antibodies against other treatment options like CAR T or other standard therapies?
- What clinical and molecular factors do you prioritize when choosing between BCMA- and GPRC5D-targeting bispecifics?
- Please comment on this study looking at talquetamab as a bridging strategy before BCMA CAR T-cell therapy, and the potential impact of bispecifics in this treatment paradigm
Advertisement
Related to this article
Ralph V. Boccia, MD, FACP, discussed educating hospital teams and using tocilizumab to manage bispecific toxicities when patients need admission.
Martin Gleave, CM, MD, FRCSC, FACS, explained how the GUNS trial is using tumor genomics to guide neoadjuvant therapy in high-risk prostate cancer.
Daniel Y.C. Heng, MD, MPH, FRCPC, explained how subsequent therapy and durable responses may have shaped overall survival results in LITESPARK-011.
Ralph V. Boccia, MD, FACP, noted how designated hospitals and a 24/7 on-call team support emergencies during bispecific step-up dosing.
Arturo Loaiza-Bonilla, MD, MSEd, FACP, co-founder of Massive Bio and system-wide chief of hematology and oncology at St. Luke’s, explains how AI is matching patients to clinical trials, where the technology falls short, and why he left academia to build what oncology was missing.
The FDA granted RMAT and fast track designations to prizlon-cel, a CD20/CD19 CAR T-cell therapy, for relapsed/refractory large B-cell lymphoma.
Ralph V. Boccia, MD, FACP, explained the caregiver’s role in monitoring and reporting during bispecific antibody step-up dosing.
Findings from the phase 3 VOLGA trial support the FDA approval of perioperative durvalumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
Subsequent Therapy May Have Narrowed the Overall Survival Gap in LITESPARK-011
2
FDA Approves Perioperative Durvalumab/Enfortumab Vedotin in MIBC
3
Managing Emergencies During Outpatient Bispecific Step-Up Dosing
4
ACS Updates Prostate Cancer Screening Guideline With Risk-Based PSA Intervals
5